0000000000008740

AUTHOR

Vija Klusa

showing 42 related works from this author

Protection of Azidothymidine-Induced Cardiopathology in Mice by Mildronate, a Mitochondria-Targeted Drug

2006

Azidothymidine, a nucleoside-analogue reverse transcriptase inhibitor (NRTI), is a commonly used antiretroviral drug in AIDS treatment, however its use is limited by severe toxic side effects due to its influence on mitochondria that result in myopathy, particularly affecting the cardiac muscle. We suggest that effective protection of azidothymidine- induced cardiopathology can be expected from drugs that are capable of targeting mitochondria. Therefore the present study in mice was carried out with mildronate, a cardioprotective drug of the aza-butyrobetaine class, which previously has been shown to act as a highly potent protector of mitochondrial processes. In our study, saline (control)…

DrugHeart Diseasesmedia_common.quotation_subjectInflammationMitochondrionPharmacologyToxicologymedicine.disease_causeMiceZidovudinemedicineAnimalsmedia_commonPharmacologyMice Inbred ICRbiologyReverse-transcriptase inhibitorCardiovascular AgentsGeneral MedicineVirologyMitochondriaDisease Models AnimalEnzyme inhibitorbiology.proteinmedicine.symptomZidovudineNucleosideOxidative stressMethylhydrazinesmedicine.drugBasic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology
researchProduct

Very low doses of muscimol and baclofen ameliorate cognitive deficits and regulate protein expression in the brain of a rat model of streptozocin-ind…

2018

Recent studies devoted to neuroprotection have focused on the role of the gamma-aminobutyric acid (GABA) system in regulating neuroinflammatory processes which play a key role in the neurodegenerative processes observed in Alzheimer's disease (AD) by inducing glial cell overactivation and impairing neurotransmission. Data on the efficacy of classical GABA-A and GABA-B receptor agonists (muscimol and baclofen, respectively) in animal models of AD are not available. Moreover, no published studies have examined the ability of optimal doses of these compounds to prevent neuroinflammation, the alterations in neurotransmission and cognitive deficits. In the present study, we used a non-transgenic…

0301 basic medicineMaleBaclofenGlutamate decarboxylaseSpatial LearningPharmacologyNeuroprotectionStreptozocin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCognitionGABA receptorSTZAlzheimer DiseaseMemoryGlial Fibrillary Acidic ProteinLearningAnimalsRats WistarNeuroinflammationPharmacologyGlial fibrillary acidic proteinbiologyDose-Response Relationship DrugChemistryGABAA receptorMuscimolBrainRatsDisease Models Animal030104 developmental biologyBaclofennervous systemMuscimolGene Expression RegulationRat model of ADbiology.protein:MEDICINE::Physiology and pharmacology::Pharmacological research [Research Subject Categories]Neuroscience030217 neurology & neurosurgeryEuropean journal of pharmacology
researchProduct

The gamma(2)-MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors.

2001

Using the latency for tail-flick after thermal stimulation we have assessed the effects of alpha-, gamma(1)- and gamma(2)-MSH on nociceptive threshold in the mice. Intracisternal injections of gamma(2)-MSH induced a distinct analgesia, while gamma(1)-MSH in the same doses gave only a minor analgesia. Intracisternal alpha-MSH instead gave a short-term hyperalgesia. The effect of gamma(2)-MSH was not blocked by any of the MC(4)/MC(3)receptor antagonist HS014, naloxone or by the prior intracisternal administrations of gamma(1)-MSH. However, the gamma(2)-MSH analgesic response was completely attenuated by treating animals with the GABA(A)antagonist bicuculline. The gamma(2)-MSH analgesic effect…

MaleNarcotic Antagonists(+)-NaloxonePharmacologyGABA Antagonistschemistry.chemical_compoundMiceEndocrinologyDrug Interactionsgamma-Aminobutyric AcidAnalgesicsMice Inbred BALB Cintegumentary systemMuscimolNaloxoneReceptors MelanocortinNociceptorsGeneral MedicineReceptor antagonistNeurologyHyperalgesiamedicine.symptomhormones hormone substitutes and hormone antagonistsmedicine.drugPain ThresholdTailendocrine systemmedicine.medical_specialtyanimal structuresmedicine.drug_classCatalepsyBicucullinePeptides CyclicCellular and Molecular Neurosciencegamma-MSHMelanocortin receptorInternal medicinemedicineAnimalsGABA ModulatorsGABA AgonistsCatalepsyDiazepamEthanolEndocrine and Autonomic SystemsAntagonistCentral Nervous System DepressantsBicucullinemedicine.diseaseEndocrinologyMuscimolchemistryReceptors Corticotropinalpha-MSHNeuropeptides
researchProduct

γ1- and γ2-melanocyte stimulating hormones induce central anxiogenic effects and potentiate ethanol withdrawal responses in the elevated plus-maze te…

2008

Little is known about the endogenous functions of gamma1- and gamma2-melanocyte stimulating hormones (gamma1- and gamma2-MSH). Although gamma-MSHs bind to melanocortin receptor subtypes 3 and 4, we have previously shown that these peptides also influence non-melanocortinergic processes, such as dopaminergic and GABAergic. The aim of this study was to determine the effects of gamma1- and gamma2-MSH (at doses 0.3, 1 and 2 nmol/mouse/5 microl) on the anxiety levels in mice in elevated plus maze. Three experimental paradigms were performed to assess the effects of peptides on: a) ethanol withdrawal; b) acute ethanol-induced anxiolytic action; c) peptides per se. We used ethanol as the model sub…

MaleElevated plus mazemedicine.medical_specialtyMelanocyte-stimulating hormonemedicine.drug_classClinical BiochemistryAnxietyToxicologyBiochemistryAnxiolyticMiceBehavioral NeuroscienceMelanocortin receptorInternal medicinemedicineAnimalsMelanocyte-Stimulating HormonesMaze LearningBiological PsychiatryPharmacologyMice Inbred ICRDose-Response Relationship DrugEthanolDopaminergicSubstance Withdrawal SyndromeEndocrinologyAnxiogenicGABAergicPsychologyHormonePharmacology Biochemistry and Behavior
researchProduct

Synthesis and pharmacological activity of silyl isoxazolines 2

2003

Silyl isoxazolines have been synthesized by [2+3] cycloaddition reaction of nitrile oxides to vinyl- and allylsilanes. The addition of 3-pyridylnitrile oxide to 1,3-divinyl-1,1,3,3-tetraphenyldisiloxane affords 1,3-bis{5-[3-(3-pyridyl)isoxazolin-2-yl]}-1,1,3,3-tetraphenyldisiloxane; the latter exists as a mixture of trans- and cis-isomers.The bond angle of the Si–O–Si fragment in thetrans-isomer equals 180(3)° and in the cis-isomer it is 162(3)°.The pharmacological properties of 4-[3-(5-trimethylsilylisoxazolin-2-yl)]pyridinium-chloride have been studied.

chemistry.chemical_compoundMolecular geometryNitrilechemistrySilylationStereochemistryOxideGeneral Materials ScienceBiological activityGeneral ChemistryMedicinal chemistryCycloadditionSilicon Chemistry
researchProduct

Neuroprotective action of diazepam at very low and moderate doses in Alzheimer's disease model rats

2018

Abstract Early manifestations of Alzheimer's disease (AD) include neuroinflammation, disrupted neurotransmission and cognitive deficits. Impairment of the GABAergic system is essentially involved in the pathogenesis of AD. Traditionally, agonists of GABAA receptors at doses above 1 mg/kg are known to possess memory impairing effects. However, we have previously found that GABAA receptor GABA site ligand muscimol at very low doses acted contrary – enhanced spatial learning/memory, as well as prevented neuroinflammation and augmented neurotransmission in AD model rats. Therefore, in the present study we focused on the assessment of the effects of non-sedative – very low (0.05 mg/kg) and moder…

Male0301 basic medicineAllosteric modulatormedicine.drug_classSynaptophysinNeurotransmissionPharmacologyHippocampusNeuroprotectionRandom Allocation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicineAlzheimer DiseasemedicineAnimalsGliosisRats Wistargamma-Aminobutyric AcidCerebral CortexPharmacologyMemory DisordersBenzodiazepineDiazepamDose-Response Relationship DrugGlutamate DecarboxylaseGABAA receptorAcetylcholineNeuroprotective Agents030104 developmental biologyGene Expression RegulationMuscimolchemistryAstrocytesSynaptic plasticityGABAergic030217 neurology & neurosurgeryNeuropharmacology
researchProduct

Taurine and tauropyrone: Comparative neuropharmacological studies of small doses

2007

Taurinechemistry.chemical_compoundchemistryTauropyronebusiness.industryPharmaceutical ScienceMedicinePharmacologybusinessEuropean Journal of Pharmaceutical Sciences
researchProduct

Opposite effects of γ1- and γ2-melanocyte stimulating hormone on regulation of the dopaminergic mesolimbic system in rats

2004

By use of the brain microdialysis technique we show that administration of gamma(1)-melanocyte stimulating hormone (gamma(1)-MSH) into the ventral tegmental area of anaesthetized rats causes an increase in the release of extracellular dopamine and its metabolite 3,4-dihydroxyphenylacetic acid in the nucleus accumbens, while gamma(2)-MSH causes the opposite effect. Moreover, gamma(2)-MSH pre-treatment considerably reduced the gamma(1)-MSH-induced effects. Our findings suggest an opposing action of two gamma-MSH-activated pathways on the mesolimbic dopaminergic system, which could be important in the maintenance of a balanced psychoactivation state.

Malemedicine.medical_specialtyMelanocyte-stimulating hormoneDopamineNucleus accumbensBiologyNucleus AccumbensRats Sprague-Dawleygamma-MSHchemistry.chemical_compoundDopamineInternal medicineNeural PathwaysLimbic SystemmedicineAnimalsNeurotransmitterBrain ChemistryNeuronsGeneral NeuroscienceVentral Tegmental AreaDopaminergicRatsUp-RegulationVentral tegmental areaEndocrinologymedicine.anatomical_structurechemistryCatecholamine34-Dihydroxyphenylacetic Acidmedicine.drugHormoneNeuroscience Letters
researchProduct

GABA-containing compound gammapyrone protects against brain impairments in Alzheimer's disease model male rats and prevents mitochondrial dysfunction…

2018

Neuroinflammation, oxidative stress, decreased glucose/energy metabolism, and disrupted neurotransmission are changes that occur early in sporadic Alzheimer's disease (AD), manifesting as mild cognitive impairment. Recently, the imbalanced function of the gamma-aminobutyric acid (GABA) system was identified as a critical factor in AD progression. Thus, maintaining balance among neurotransmitter systems, particularly the GABA system, can be considered a beneficial strategy to slow AD progression. The present study investigated the effects of the compound gammapyrone, a molecule containing three GABA moieties: "free" moiety attached to the position 4 of the 1,4-dihydropyridine (DHP) ring, and…

0301 basic medicineMalemedicine.medical_specialtyAllosteric regulationbioenergetics; GABA; intracerebroventricular streptozocin; PC12 cells; protein expression; spatial learning/memoryNeurotransmissionspatial learning/memorymedicine.disease_causebioenergeticsNeuroprotection03 medical and health sciencesCellular and Molecular NeuroscienceGABA0302 clinical medicineReceptors GABAAlzheimer DiseaseMemoryInternal medicinemedicineAnimalsRats WistarReceptorMaze Learningprotein expressionNeuroinflammationCells Culturedgamma-Aminobutyric AcidGABAA receptorChemistryGlutamate DecarboxylasePC12 cellsBrainintracerebroventricular streptozocinMitochondriaStreptozocinDisease Models Animal030104 developmental biologyEndocrinologyNeuroprotective AgentsAstrocytesAcetylcholinesteraseEncephalitisMicroglia030217 neurology & neurosurgeryOxidative stressJournal of neuroscience research
researchProduct

Intra-Nasally Administered Oligopeptide Lunasin Acts as a Possible Anti-Psychotic Agent in Mice Models

2019

Background and Objectives: Previously we have shown that synthetic lunasin, a 43 amino acid residue-containing peptide, after its central (intracisternal) administration in mice demonstrated antagonism against dopaminergic drug behavioural effects, indicating a putative antipsychotic/anti-schizophrenic profile of lunasin. The aims of the present studies were: to test whether lunasin would show an influence on the dopaminergic system after intranasal administration, and to examine the effect(s) of lunasin on serotonin and glutamatergic systems, which could play an essential role in antipsychotic action. Materials and Methods: Lunasin was administered intra-nasally at doses 0.1 and 1 nmol/mou…

AgonistMedicine (General)medicine.drug_classreceptor bindingbrain monoaminesPharmacologyMotor ActivityLunasinArticleintranasal administration03 medical and health sciencesMiceR5-9200302 clinical medicinehyper-locomotionmedicineAnimalslunasin; intranasal administration; hyper-locomotion; brain monoamines; receptor bindingAmphetaminePhencyclidine5-HT receptorAdministration IntranasalMice Inbred ICRChemistrylunasinAmphetaminesGeneral MedicineDisease Models AnimalMonoamine neurotransmitter030220 oncology & carcinogenesisNMDA receptorSerotoninOligopeptides030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsMedicina; Volume 55; Issue 7; Pages: 393
researchProduct

Comparative study of taurine and tauropyrone: GABA receptor binding, mitochondrial processes and behaviour.

2011

Abstract Objectives Taurine, a sulfur-containing amino acid, has high hydrophilicity and is poorly absorbed. Tauropyrone, a taurine-containing 1,4-dihydropyridine derivative, is suggested to have greater activity than taurine owing to improved physicochemical properties that facilitate delivery of the compound to target cells. The aim of this study was to determine whether the 1,4-dihydropyridine moiety in tauropyrone improves the pharmacological efficacy of taurine in vitro and in vivo. Methods The effects of taurine and tauropyrone, as well as of the 1,4-dihydropyridine moiety were compared in in-vitro experiments to determine the binding to GABA receptors and influence on mitochondrial p…

Malemedicine.medical_specialtyTaurineDihydropyridinesGABA receptor bindingTaurinePharmaceutical SciencePharmacologyMotor ActivityBicucullinechemistry.chemical_compoundMiceStructure-Activity RelationshipIn vivoSeizuresInternal medicinemedicineStructure–activity relationshipAnimalsRats WistarReceptorPharmacologychemistry.chemical_classificationMice Inbred ICRDiazepamBehavior AnimalEthanolChemistryGABAA receptorBicucullineReceptors GABA-AAmino acidMitochondriaRatsEndocrinologyMuscle TonusRotarod Performance TestEnergy MetabolismHydrophobic and Hydrophilic Interactionsmedicine.drugProtein BindingThe Journal of pharmacy and pharmacology
researchProduct

Mildronate enhances learning/memory and changes hippocampal protein expression in trained rats.

2013

Previously we demonstrated that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a representative of the aza-butyrobetaine class of compounds, protects mitochondrial metabolism under conditions such as ischemia. Mildronate also acted as a neuroprotective agent in an azidothymidine-induced mouse model of neurotoxicity, as well as in a rat model of Parkinson's disease. These observations suggest that mildronate may stimulate processes involved in cell survival and change expression of proteins involved in neurogenic processes. The present study investigated the influence of mildronate on learning and memory in the passive avoidance response (PAR) test and the active condition…

MaleClinical BiochemistryGlutamate decarboxylaseBlotting WesternNerve Tissue ProteinsPharmacologyHippocampal formationToxicologyBiochemistryNeuroprotectionHippocampusBehavioral Neurosciencechemistry.chemical_compoundMemorymedicineAnimalsLearningRats WistarBiological PsychiatryPharmacologyChemistryGlutamate DecarboxylaseNeurotoxicitymedicine.diseaseAcetylcholinesteraseNeural stem cellRatsBromodeoxyuridineAcetylcholinesteraseCholinergicNeuroscienceBromodeoxyuridineMethylhydrazinesPharmacology, biochemistry, and behavior
researchProduct

The differential influences of melanocortins on nociception in the formalin and tail flick tests

2006

Melanocortins exert multiple physiological effects that include the modulation of immune responses, inflammation processes, and pain transmission. In the present study we investigated the peripheral activity of natural melanocortins - alpha-, beta-, gamma1- and gamma2-melanocyte stimulating hormone (MSH) - and melanocortin receptor subtypes 3 and 4 (MC3/4 receptor) antagonist HS014 in pain (formalin and tail flick) tests after peptide subcutaneous administration in mice. In the formalin test, among all substances tested only alpha-MSH (1 micromol/kg) statistically significantly inhibited the formalin-induced first phase pain response, however, all tested peptides (except gamma1-MSH) at the …

Maleendocrine systemmedicine.medical_specialtyMelanocyte-stimulating hormonemedicine.drug_classClinical BiochemistryAnalgesicNitric OxideToxicologyPeptides CyclicBiochemistryMicegamma-MSHBehavioral NeuroscienceMelanocortin receptorInternal medicinebeta-MSHmedicineAnimalsBiological PsychiatryPain MeasurementMelanocortinsPharmacologyAnalgesicsMice Inbred ICRintegumentary systemChemistryReceptors MelanocortinAntagonistReceptor antagonistMelanocortinsNociceptionEndocrinologyalpha-MSHhormones hormone substitutes and hormone antagonistsTail flick testPharmacology Biochemistry and Behavior
researchProduct

Targeting the Mitochondria by Novel Adamantane-Containing 1,4-Dihydropyridine Compounds

2012

Linda Klimaviciusa1, Maria A. S. Fernandes2, Nelda Lencberga1, Marta Pavasare1, Joaquim A. F. Vicente2, Antonio J. M. Moreno2, Maria S. Santos3, Catarina R. Oliveira4, Imanta Bruvere5, Egils Bisenieks5, Brigita Vigante5 and Vija Klusa1 1Department of Pharmacology, Faculty of Medicine, University of Latvia, Riga 2IMAR-CMA, Department of Life Sciences, University of Coimbra, Coimbra 3CNC, Department of Life Sciences, University of Coimbra, Coimbra 4CNC, Faculty of Medicine, University of Coimbra, Coimbra 5Laboratory of Membrane Active and beta-Diketone Compounds, Latvian Institute of Organic Synthesis, Riga 2,3,4Portugal 1,5Latvia

chemistry.chemical_compoundchemistryAdamantanemedia_common.quotation_subjectDihydropyridinemedicineLibrary scienceArtmedia_commonmedicine.drug
researchProduct

Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1,4-dihydropyridine…

2014

The novel 1,4-dihydropyridine derivatives containing the cationic pyridine moiety at the position 4, and the N-propargyl group as a substituent at position 1 of the 1,4-DHP cycle were designed, synthesised, and assessed in biological tests. Among all the novel compounds, the 4-(N-dodecyl) pyridinium group-containing compounds 11 (without the N-propargyl group) and 12 (with the N-propargyl group) demonstrated the highest calcium antagonistic properties against neuroblastoma SH-SY5Y (IC50 about 5–14 mM) and the vascular smooth muscle A7r5 cell (IC50 – 0.6–0.7 mM) lines, indicating that they predominantly target the L-type calcium channels. These compounds showed a slight total antioxidant act…

AntioxidantVoltage-dependent calcium channelChemistryStereochemistryGeneral Chemical EngineeringCalcium channelmedicine.medical_treatmentSubstituentCationic polymerizationchemistry.chemical_elementGeneral ChemistryCalciumN-Dodecyl pyridiniumMitochondrial processesStructure–activity relationshipschemistry.chemical_compound14-DihydropyridinesAntioxidant activityPropargylmedicineCalcium antagonistsPyridiniumPropargyl substituentComptes Rendus Chimie
researchProduct

Anti-Neurotoxic Effects of Tauropyrone, a Taurine Analogue

2006

Taurinechemistry.chemical_compoundTauropyroneChemistryPharmacologyFree Radical Formation
researchProduct

Lunasin-induced behavioural effects in mice: Focus on the dopaminergic system

2013

The present study for the first time is devoted to identify central effects of synthetic lunasin, a 43 amino acid peptide. A markedly expressed neuroleptic/cataleptic effect was observed at low (0.1-10 nmol/mouse) centrally administered doses in male C57Bl/6 mice. Lunasin considerably reduced the amphetamine hyperlocomotion but weakly apomorphine climbing behaviour. No influence on ketamine and bicuculline effects was observed. Binding assay studies demonstrated modest affinity of lunasin for the dopamine D₁ receptor (Ki=60 ± 15 μM). In a functional assay of cAMP accumulation on live cells lunasin antagonised apomorphine effect on D₁ receptor activation (pEC₅₀=6.1 ± 0.3), but had no effect …

Malemedicine.medical_specialtyApomorphineDopamine AgentsMotor ActivityPharmacologyBicucullineLunasinBehavioral NeuroscienceDopamine receptor D1SeizuresDopamineInternal medicineCyclic AMPmedicineAnimalsHumansGABA-A Receptor AntagonistsAmphetamineReceptorCatalepsyReceptors Dopamine D2ChemistryReceptors Dopamine D1DopaminergicBrainMice Inbred C57BLApomorphineAmphetamineHEK293 CellsEndocrinologyDopamine receptorSoybean ProteinsKetamineExcitatory Amino Acid AntagonistsCentral Nervous System Agentsmedicine.drugBehavioural Brain Research
researchProduct

3,4-trans-4-Aryl-3-(1-pyridinio)-1,2,3,4-tetrahydropyridine-6-thiolates—new group of potential cardiotonic drugs

2005

Abstract 3,4- trans -4-Aryl-3-(1-pyridinio)-1,2,3,4-tetrahydropyridine-6-thiolates 6 – 11 were prepared by a Michael reaction of N -acetonylpyridinium chloride with 3-aryl-2-cyanothioacrylamides or by a one-pot three-carbon condensation of N -acetonylpyridinium chloride, aromatic aldehyde and 2-cyanothioacetamide, and their cardiotonic properties were studied. 3,4- trans -5-cyano-2-hydroxy-2-methyl-4-(3-nitrophenyl)-3-(1-pyridinio)-1,2,3,4-tetrahydropyridine-6-thiolate 8 was considered as a lead compound in this series since it in vitro experiments (spontaneously beating rat atria) showed a cardiotonic activity similar to that of milrinone 2 , however compound 8 induced activity at lover co…

ChronotropicCardiotonic AgentsPyridinesStereochemistryGuinea PigsBlood PressureCardiac activityIn Vitro TechniquesCardiotonic AgentsAldehydeChlorideChemical synthesischemistry.chemical_compoundHeart RateGroup (periodic table)Drug DiscoverymedicineAnimalsSulfhydryl CompoundsRats WistarPharmacologychemistry.chemical_classificationCardiotonic drugsArylOrganic ChemistryGeneral MedicineRatschemistryMilrinoneLead compoundMilrinonemedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Neuroprotective properties of mildronate, a mitochondria-targeted small molecule.

2010

Mildronate, a representative of the aza-butyrobetaine class of drugs with proven cardioprotective efficacy, was recently found to prevent dysfunction of complex I in rat liver mitochondria. The present study demonstrates that mildronate also acts as a neuroprotective agent. In a mouse model of azidothymidine (anti-HIV drug) neurotoxicity, mildronate reduced the azidothymidine-induced alterations in mouse brain tissue: it normalized the increase in caspase-3, cellular apoptosis susceptibility protein (CAS) and iNOS expression assessed by quantitative and semi-quantitative analysis. Mildronate also normalized the changes in cytochrome c oxidase (COX) expression, reduced the expression of glia…

MaleCell signalingAnti-HIV AgentsNitric Oxide Synthase Type IIMice Inbred StrainsMitochondrionPharmacologyNeuroprotectionElectron Transport Complex IVMiceCellular Apoptosis Susceptibility ProteinGlial Fibrillary Acidic ProteinmedicineAnimalsLymphocytesNeuroinflammationGlial fibrillary acidic proteinbiologyCaspase 3General NeuroscienceNeurodegenerationNeurotoxicityBrainmedicine.diseaseDisease Models AnimalNeuroprotective AgentsBiochemistrybiology.proteinNeurotoxicity SyndromesZidovudineCellular apoptosis susceptibility proteinMethylhydrazinesNeuroscience letters
researchProduct

The effects of glutamate receptor antagonists on cerebellar granule cell survival and development.

2007

N-Methyl-d-aspartate (NMDA) receptor stimulation promotes neuronal survival and differentiation under both in vitro and in vivo conditions. We studied the effects of various NMDA receptor antagonists acting at different NMDA receptor binding sites and non-NMDA receptor antagonists on the development and survival of cerebellar granule cell (CGC) culture. Only three of the drugs tested induced neurotoxicity-MK-801 (non-competitive NMDA channel blocking antagonist), ifenprodil (an antagonist of the NR2B site and polyamine site of the NMDA receptor) and L-701.324 (full antagonist at glycine site), while CGP-37849 (a competitive NMDA antagonist), (+)-HA-966 (a partial agonist of the glycine site…

N-MethylaspartateTime FactorsNeuriteCell SurvivalGlutamic AcidTetrazolium SaltsAMPA receptorPharmacologyBiologyToxicologyNeuroprotectionchemistry.chemical_compoundCerebellumIfenprodilExcitatory Amino Acid AgonistsIn Situ Nick-End LabelingAnimalsDrug InteractionsRats WistarCells CulturedNeuronsAnalysis of VarianceCell DeathDose-Response Relationship DrugGeneral NeuroscienceGlutamic acidRatsThiazolesnervous systemchemistryBiochemistryAnimals NewbornCompetitive antagonistNMDA receptorNBQXExcitatory Amino Acid AntagonistsNeurotoxicology
researchProduct

A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweD…

2015

Ca2+ blockers, particularly those capable of crossing the blood-brain barrier (BBB), have been suggested as a possible treatment or disease modifying agents for neurodegenerative disorders, e.g., Alzheimer's disease. The present study investigated the effects of a novel 4-(N-dodecyl) pyridinium group-containing 1,4-dihydropyridine derivative (AP-12) on cognition and synaptic protein expression in the brain. Treatment of AP-12 was investigated in wild type C57BL/6J mice and transgenic Alzheimer's disease model mice (Tg APPSweDI) using behavioral tests and immunohistochemistry, as well as mass spectrometry to assess the blood-brain barrier (BBB) penetration. The data demonstrated the ability …

Genetically modified mouseMalePathologymedicine.medical_specialtyDihydropyridinesTime Factorsmedicine.drug_classTransgeneSpatial Learninglcsh:MedicineMice TransgenicBlood–brain barrierAnxiolyticGyrus CinguliHippocampus03 medical and health sciences0302 clinical medicineHomer Scaffolding ProteinsMemorymedicineAnimalsHumanslcsh:Science030304 developmental biology0303 health sciencesMultidisciplinaryAmyloid beta-PeptidesGlutamate Decarboxylaselcsh:RDihydropyridineWild typeBrainmedicine.disease3. Good healthMice Inbred C57BLmedicine.anatomical_structureAnti-Anxiety AgentsBlood-Brain BarrierSynaptic plasticitylcsh:QAlzheimer's diseaseCarrier ProteinsNeuroscience030217 neurology & neurosurgerymedicine.drugResearch ArticlePloS one
researchProduct

Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease

2011

Background. Mildronate (3-[2,2,2-trimethylhydrazinium] propionate dihydrate) traditionally is a well-known cardioprotective drug. However, our recent studies convincingly demonstrated its neuroprotective properties. The aim of the present study was to evaluate the influence of mildronate on the expression of proteins that are involved in the differentiation and survival of the nigrostriatal dopaminergic neurons in the rat model of Parkinson’s disease (PD). The following biomarkers were used: heat shock protein 70 (Hsp70, a molecular chaperone), glial cell line-derived nerve growth factor (GDNF, a growth factor promoting neuronal differentiation, regeneration, and survival), and neural cell …

biologybusiness.industryGrowth factormedicine.medical_treatmentSubstantia nigraGeneral MedicineStriatumPharmacologyNeuroprotectionHsp70Nerve growth factornervous systemmedicineGlial cell line-derived neurotrophic factorbiology.proteinmildronate; protein expression; neuroprotectionNeural cell adhesion moleculebusinessMedicina
researchProduct

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

2010

Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); …

MaleNitric Oxide Synthase Type IIlcsh:ChemistryUbiquitinNeurotoxinlcsh:QH301-705.5Receptor Notch3SpectroscopyNeuronsReceptors NotchbiologyGlial fibrillary acidic proteinMicrofilament ProteinsGeneral MedicineComputer Science ApplicationsCell biologySubstantia NigraNitric oxide synthaseNeuroprotective Agentsmedicine.anatomical_structureBiochemistryNeurogliaNeurogliaMethylhydrazinesneuroimmunological biomarkersTyrosine 3-Monooxygenasesmall moleculeSubstantia nigraParkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small moleculeNeuroprotectionArticleCatalysisInorganic ChemistryGlial Fibrillary Acidic ProteinmedicineAnimalsParkinson Disease SecondaryRats WistarPhysical and Theoretical ChemistryOxidopamineMolecular BiologyTyrosine hydroxylase6-OHDA modelCalcium-Binding ProteinsmildronateOrganic ChemistryCorpus StriatumRatslcsh:Biology (General)lcsh:QD1-999nervous systemParkinson’s diseasebiology.proteinBiomarkersInternational Journal of Molecular Sciences
researchProduct

Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease.

2020

Abstract The earliest hallmarks of sporadic Alzheimer's disease (sAD) are impaired glucose metabolism, chronic neuroinflammation, diminished synaptic plasticity and subsequent cognitive decline. The safest antidiabetic drug metformin has shown both glucose metabolism-improving and cognition-enhancing action in type 2 diabetes patients and diabetic model animals. However, metformin has not been previously studied in intracerebroventricular streptozocin (STZ)-induced model of sAD. Therefore, our aim was to assess the preventive action of metformin in sAD model-rats. Firstly, the actions of metformin (75 and 100 mg/kg) on cognitive functions and sociability were examined. Secondly, we wanted t…

0301 basic medicineMaleendocrine system diseasesNerve Tissue ProteinsType 2 diabetesPharmacologyGPI-Linked ProteinsNeuroprotectionStreptozocin03 medical and health sciencesGlycogen Synthase Kinase 30302 clinical medicineCognitionAlzheimer DiseaseMorris Water Maze TestMedicineAnimalsHypoglycemic AgentsCognitive declineRats WistarSocial BehaviorNeuroinflammationInjections IntraventricularPharmacologyGlucose Transporter Type 1Behavior AnimalGlucose Transporter Type 3business.industrydigestive oral and skin physiologyGlucose transporternutritional and metabolic diseasesBrainmedicine.diseaseMetforminMetforminAstrogliosisDisease Models Animal030104 developmental biologyGlucoseNeuroprotective AgentsSynaptic plasticityAcetylcholinesterasebusinessNeuroglia030217 neurology & neurosurgerymedicine.drugEuropean journal of pharmacology
researchProduct

Neuroinflammation and acetylcholinesterase overexpression as the main targets for low doses of GABA-A receptor agonists in Alzheimer's disease rat mo…

2018

GABA-A Receptor Agonistschemistry.chemical_compoundChemistryApplied MathematicsGeneral MathematicsLow doseRat modelDiseasePharmacologyAcetylcholinesteraseNeuroinflammationProceedings for Annual Meeting of The Japanese Pharmacological Society
researchProduct

The Fundamental Role of Melanocortins in Brain Processes

2003

The discoveries of the latest ten years have shed new light in understanding the roles of melanocortins and their receptors in brain functions and in the development of different pathologies. Since 1992 when genes encoded melanocortin receptor five subtypes were identified, cloned and characterized, the molecular mechanisms underlying different effects such as skin darkening, behaviour, food intake, anti-inflammatory action, analgesia have been clarified. The contribution of melanocortins and their receptors in the physiological control of organism homeostasis has become as the background for the search of agonists and antagonists of separate receptor subtypes, that can be targeted to the m…

integumentary systemdigestive oral and skin physiologyBiologyVentral tegmental areamedicine.anatomical_structureImmune systemMelanocortin receptormedicineACTH receptorMelanocortinReceptorNeuroscienceOrganismMelanocortins
researchProduct

Carnitine congener mildronate protects against stress- and haloperidol-induced impairment in memory and brain protein expression in rats.

2014

The present study investigates the efficacy of mildronate, a carnitine congener, to protect stress and haloperidol-induced impairment of memory in rats and the expression of brain protein biomarkers involved in synaptic plasticity, such as brain-derived neurotrophic factor (BDNF), acetylcholine esterase and glutamate decarboxylase 67 (GAD67). Two amnesia models were used: 2h immobilization stress and 3-week haloperidol treatment. Stress caused memory impairment in the passive avoidance test and induced a significant 2-fold BDNF elevation in hippocampal and striatal tissues that was completely inhibited by mildronate. Mildronate decreased the level of GAD67 (but not acetylcholine esterase) e…

Malemedicine.medical_specialtyGlutamate decarboxylaseAmnesiaNerve Tissue ProteinsHippocampal formationGPI-Linked ProteinsNeurotrophic factorsMemoryStress PhysiologicalInternal medicineCarnitinemedicineHaloperidolAvoidance LearningMemory impairmentAnimalsCarnitineRats WistarMaze LearningPharmacologyChemistryGlutamate DecarboxylaseBrain-Derived Neurotrophic FactorBrainRatsEndocrinologyNeuroprotective AgentsSynaptic plasticityAcetylcholinesteraseHaloperidolmedicine.symptomNeuroscienceBiomarkersmedicine.drugMethylhydrazinesEuropean journal of pharmacology
researchProduct

Search for Stroke-Protecting Agents in Endothelin-1-Induced Ischemic Stroke Model in Rats

2012

Background and Objective. Ischemic stroke may initiate a reperfusion injury leading to brain damage cascades where inflammatory mechanisms play a major role. Therefore, the necessity for the novel stroke-protecting agents whose the mechanism of action is focused on their anti-inflammatory potency is still on the agenda for drug designers. Our previous studies demonstrated that cerebrocrast (a 1,4-dihydropyridine derivative) and mildronate (a representative of the aza-butyrobetaine class) possessed considerable anti-inflammatory and neuroprotective properties in different in vitro and in vivo model systems. The present study investigated their stroke-protecting ability in an endothelin-1 (ET…

MaleDihydropyridinesDrug Evaluation PreclinicalInfarctionBrain damagePharmacologyNeuroprotectionIn vivomedicineAnimalsRats WistarStrokeEndothelin-1business.industryGeneral Medicinemedicine.diseaseRatsStrokeDisease Models AnimalNeuroprotective AgentsMechanism of actionendothelin-1; ischemic stroke; neurodegeneration; protection; cerebrocrast; mildronateDrug Therapy Combinationmedicine.symptombusinessReperfusion injuryEx vivoMethylhydrazinesMedicina; Volume 48; Issue 10; Pages: 77
researchProduct

Atypical 1,4-dihydropyridine derivatives, an approach to neuroprotection and memory enhancement

2016

This mini review is devoted to the design and pharmacological studies of novel atypical 1,4-dihydropyridine (DHP) derivatives which differ to a great extent from the traditional DHPs either by lack of neuronal calcium channel blocking activity and/or inability to protect mitochondrial processes. About 100 new DHP derivatives were screened and the mostly active were selected for detailed studies. The compounds of the series of the amino acid ("free" plus "crypto")-containing DHPs and lipophilic di-cyclic DHPs demonstrated long-lasting neuroprotective and/or memory-enhancing action, particularly at low doses (0.005-0.05mg/kg) in different neurodeficiency rat or mice models, and exerted neurot…

0301 basic medicineGenetically modified mouseDihydropyridinesDHPSNeurotransmissionBiologyPharmacologyNeuroprotection03 medical and health sciences0302 clinical medicineMemoryAnimalsHumansPharmacologychemistry.chemical_classificationNeurotransmitter AgentsCalcium channelCalcium Channel BlockersNeuroprotectionAmino acid030104 developmental biologychemistrySynaptic plasticityNervous System DiseasesNeurotransmitter AgentsNeuroscience030217 neurology & neurosurgeryPharmacological Research
researchProduct

Pilot study to evaluate the assessment methods of the basic pharmacology course at the Faculty of Medicine of the University of Latvia

2018

Medical educationbusiness.industryApplied MathematicsGeneral MathematicsAssessment methodsMedicinebusinessCourse (navigation)Proceedings for Annual Meeting of The Japanese Pharmacological Society
researchProduct

Mildronate improves cognition and reduces amyloid-β pathology in transgenic Alzheimer's disease mice

2013

Mildronate, a carnitine congener drug, previously has been shown to provide neuroprotection in an azidothymidine-induced mouse model of neurotoxicity and in a Parkinson's disease rat model. The aim of this study was to investigate the effects of mildronate treatment on cognition and pathology in Alzheimer's disease (AD) model mice (APP(SweDI)). Mildronate was administered i.p. daily at 50 or 100 mg/kg for 28 days. At the end of treatment, the animals were behaviorally and cognitively tested, and brains were assessed for AD-related pathology, inflammation, synaptic markers, and acetylcholinesterase (AChE). The data show that mildronate treatment significantly improved animal performance in w…

Genetically modified mousePathologymedicine.medical_specialtybiologyNeurotoxicityHippocampusWater mazemedicine.diseaseAcetylcholinesteraseNeuroprotectionCellular and Molecular Neurosciencechemistry.chemical_compoundchemistrySynaptic plasticitymedicineSynaptophysinbiology.proteinPsychologyJournal of Neuroscience Research
researchProduct

Potato (Solanum tuberosum) Juice Exerts an Anticonvulsant Effect in Mice through Binding to GABA Receptors

2008

Naturally occurring benzodiazepines have been identified in regular food such as wheat and potato, but there is still no evidence that potato extracts can affect CNS responses in vivo. Here we found that undiluted potato juice and potato juice diluted with saline 1 : 2 administered 10 min intracisternally ( I. C.) and 30 min per os before bicuculline exerted significant anticonvulsant activity in the bicuculline-induced seizure threshold test in mice. In vitro, potato juice from different harvests at dilution series from 10 % to 0.000001 %, diluted 100,000-fold, displaced 50 % of gamma-aminobutyric acid (GABA) receptor ligand [ (3)H]GABA and diluted 40-fold displaced 50 % of [(3)H]flunitraz…

Malemedicine.medical_treatmentPharmaceutical SciencePharmacologyPharmacognosyBicucullineMass SpectrometryAnalytical ChemistryMiceReceptors GABAIn vivoDrug DiscoverymedicineAnimalsChromatography High Pressure LiquidSolanum tuberosumPharmacologyMice Inbred ICRDiazepamBehavior AnimalSeizure thresholdPlant ExtractsGABAA receptorChemistryAlkaloidfungiOrganic Chemistryfood and beveragesBicucullineAnticonvulsantComplementary and alternative medicineBiochemistryMolecular MedicineAnticonvulsantsFlunitrazepammedicine.drugPlanta Medica
researchProduct

Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improves Motor Symptoms and Normalizes Tyrosine Hydroxylase E…

2018

Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting millions of people worldwide. At present, there is no effective cure for PD; treatments are symptomatic and do not halt progression of neurodegeneration. Extracellular vesicles (EVs) can cross the blood–brain barrier and represent promising alternative to the classical treatment strategies. In the present study, we examined therapeutic effects of intranasal administration of EVs derived from human exfoliated deciduous teeth stem cells (SHEDs) on unilateral 6-hydroxydopamine (6-OHDA) medial forebrain bundle (MFB) rat model of PD. CatWalk gait tests revealed that EVs effectively suppressed 6-OHDA-…

0301 basic medicineMaleCell signalingParkinson's diseaseParkinson's diseaseStriatumPharmacology0302 clinical medicineMedicineMedial forebrain bundleAdult stem cellsStem CellsNeurodegenerationParkinson DiseaseGeneral MedicineAnimal modelsSubstantia NigraDifferentiationmedicine.symptom:MEDICINE::Physiology and pharmacology::Pharmacological research [Research Subject Categories]Tyrosine 3-MonooxygenaseCellular therapySubstantia nigraLesion03 medical and health sciencesExtracellular VesiclesMicroscopy Electron TransmissionTissue Engineering and Regenerative MedicineAnimalsHumansRats WistarOxidopamineAdministration IntranasalAgedHydroxydopamineTyrosine hydroxylasebusiness.industryCell Biologymedicine.diseaseCorpus StriatumRatsDisease Models Animal030104 developmental biologynervous systemMesenchymal stem cellsbusinessTooth030217 neurology & neurosurgeryDevelopmental BiologyStem cells translational medicine
researchProduct

Distinct influence of atypical 1,4-dihydropyridine compounds in azidothymidine-induced neuro- and cardiotoxicity in mice ex vivo.

2008

This study demonstrates the effective protection by compounds of atypical 1,4-dihydropyridine (DHP) series cerebrocrast, glutapyrone and tauropyrone against neuro- and cardiotoxicity caused by the model compound azidothymidine, a well-known mitochondria-compromising anti-HIV drug. In previous in vitro experiments, we have demonstrated distinct effects of these DHP compounds to influence mitochondrial functioning. In the present in vivo experiments, DHP compounds were administered intraperitoneally in mice daily for 2 weeks, per se and in combinations with azidothymidine at doses: azidothymidine 50 mg/kg; cerebrocrast 0.1 mg/kg; glutapyrone 1 mg/kg; and tauropyrone 1 mg/kg. At the end of the…

MaleDihydropyridinesHeart DiseasesRatónAnti-HIV AgentsTaurineApoptosisBiologyPharmacologyToxicologyMiceGlutamatesIn vivomedicineAnimalsPharmacologyCerebral CortexInflammationCardiotoxicityMice Inbred ICRCaspase 3DihydropyridineTranscription Factor RelAGeneral MedicineBiochemistryGene Expression RegulationEnzyme inhibitorApoptosisToxicitybiology.proteinNeurotoxicity SyndromesZidovudineEx vivomedicine.drugBasicclinical pharmacologytoxicology
researchProduct

GABAA agonist muscimol ameliorates learning/memory deficits in streptozocin-induced Alzheimer’s disease non-transgenic rat model

2015

Background: GABAergic inhibitory action regulates learning/memory processes and contributes to neurotransmission (Gong et al., 2009). Existing evidence suggests GABAergic system is involved in pathophysiology of Alzheimer’s disease (AD) via inhibitory interneuron deficits (Verret et al., 2012) and decrease in functional GABAA receptors (Limon et al., 2012). In vitro, GABA and muscimol (GABAA receptor agonist) blocked neuronal death induced by Aβ in rat hippocampal and cortical neurons (Paula-Lima et al., 2005). Our concept: low doses of muscimol may prevent learning/memory deficits in intracerebroventricular (icv) streptozocin (STZ)-induced AD non-transgenic rat model. Methods. Wistar male …

Agonistmedicine.medical_specialtymedicine.drug_class02 engineering and technologyWater mazeNeurotransmissionHippocampal formationInhibitory postsynaptic potential030226 pharmacology & pharmacymemory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicineMultidisciplinarybusiness.industryGABAA receptorstreptozocin021001 nanoscience & nanotechnologymuscimol3. Good healthEndocrinologynervous systemMuscimolchemistryAnesthesiaPoster PresentationGABAergic0210 nano-technologybusinessSpringerPlus
researchProduct

Betulin binds to gamma-aminobutyric acid receptors and exerts anticonvulsant action in mice.

2007

The lupane type pentacyclic triterpenes: lupeol, betulin, and betulinic acid are widely distributed natural compounds. Recently, pharmaceutical compositions from plant extracts (family Marcgraviaceae) containing betulinic acid, have been patented as anxiolytic remedies. To extend our knowledge of the CNS effects of the triterpenes, we suggest here that the chemically related lupeol, betulin and betulinic acid may interact with the brain neurotransmitter gamma-aminobutyric acid (GABA) receptors in vitro and in vivo. Using radioligand receptor-binding assay, we showed that only betulin bound to the GABA(A)-receptor sites in mice brain in vitro and antagonised the GABA(A)-receptor antagonist b…

Malemedicine.medical_treatmentClinical BiochemistryAntineoplastic AgentsFlunitrazepamPharmacologyBiologyToxicologyBicucullineBiochemistryAminobutyric acidBehavioral Neurosciencechemistry.chemical_compoundMiceReceptors GABAIn vivoSeizuresBetulinic acidmedicineAnimalsBetulinic AcidReceptorGABA ModulatorsPostural BalanceBiological Psychiatrygamma-Aminobutyric AcidLupeolPharmacologyMice Inbred ICRBetulinAnti-Inflammatory Agents Non-SteroidalTriterpenesAnticonvulsantBiochemistrychemistryMuscle TonusAnticonvulsantsPentacyclic TriterpenesPentacyclic TriterpenesPharmacology, biochemistry, and behavior
researchProduct

Anti-inflammatory effects of cerebrocrast in a model of rat paw edema and on mononuclear THP-1 cells.

2002

Cerebrocrast (IOS 1.1212; 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid di(2-propoxyethyl) diester) is a novel derivative of 1,4-dihydropyridine, which does not antagonize Ca(2+) influx in neuronal tissues. Since several classical dihydropyridines possess anti-inflammatory properties, we first studied the effects of cerebrocrast in a model of rat paw edema induced by carrageenan. Cerebrocrast had a preventative effect in this model of inflammation, with maximal activity (32-45% inhibition) in the 0.1-0.25 mg kg(-1) range. It was ineffective when added after the injection of carrageenan. Subsequent in vitro experiments showed that cerebrocrast in the mi…

Malemedicine.medical_specialtyDihydropyridinesmedicine.drug_classmedicine.medical_treatmentAnti-Inflammatory AgentsInflammationNeuroprotectionAnti-inflammatoryMonocyteschemistry.chemical_compoundInternal medicineForelimbmedicineTumor Cells CulturedAnimalsEdemaHumansTHP1 cell lineRats WistarPharmacologyDose-Response Relationship Drugbusiness.industryBiological activityCarrageenanRatsDisease Models AnimalEndocrinologyCytokinechemistryTumor necrosis factor alphamedicine.symptombusinessEuropean journal of pharmacology
researchProduct

Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer’s disease transgenic female mice

2016

The prevalence of Alzheimer's disease (AD) is higher in females than in males, and causes more severe cognitive, memory and behavioral impairments. Previously, in male transgenic (Tg) APPSweDI mice, we reported that the novel lipophilic 1,4-dihydropyridine (DHP) derivative AP-12 crossed the blood-brain barrier, blocked neuronal and vascular calcium channels, changed brain protein expression and improved behavior. In this study, we used female Tg APPSweDI mice to assess the effects of AP-12 on behavior, and brain protein expression, with a particular focus on those of the GABAergic system. The results showed that in female Tg mice, similar to male Tg mice, AP-12 improved spatial learning/mem…

Male0301 basic medicineCingulate cortexDihydropyridinesmedicine.medical_specialtyElevated plus mazeVesicular Inhibitory Amino Acid Transport ProteinsHippocampusMice TransgenicWater mazeBiologyHippocampal formationGyrus CinguliHippocampusArticleAmyloid beta-Protein PrecursorMice03 medical and health sciences0302 clinical medicineAlzheimer DiseaseMemoryInternal medicineNeuroplasticitymedicineAnimalsGABAergic NeuronsMaze LearningPharmacologyAmyloid beta-PeptidesNeuronal PlasticityGlutamate DecarboxylaseCalcium Channel BlockersUp-RegulationDisease Models Animal030104 developmental biologyEndocrinologyAnti-Anxiety AgentsBlood-Brain BarrierSynaptic plasticityGABAergicCalciumFemale030217 neurology & neurosurgeryPharmacological Research
researchProduct

Distinct effects of atypical 1,4-dihydropyridines on 1-methyl-4-phenylpyridinium-induced toxicity.

2006

Our previous data obtained from in vivo experiments demonstrated high neuroprotective effects of three novel atypical neuronal non-calcium antagonistic 1,4-dihydropyridine (DHP) derivatives cerebrocrast, glutapyrone and tauropyrone. The present studies were carried out in vitro to clarify, at least in part, their mechanism of action in primary culture of cerebellar granule cells by use of 1-methyl-4-phenylpyridinium (MPP+) as a neurotoxic agent which causes dramatic oxidative stress. Cerebrocrast (highly lipophilic, with a classical two-ring structure) dose-dependently (0.01-10.0 microM, EC50 = 13 nM) reduced MPP+-induced cell death. At the same time, the calcium antagonist nimodipine (refe…

Membrane potentialNeurons1-Methyl-4-phenylpyridiniumDihydropyridinesCell DeathMolecular Structure1-Methyl-4-phenylpyridiniumClinical BiochemistryCell BiologyGeneral MedicineMitochondrionPharmacologyBiologymedicine.disease_causeBiochemistryNeuroprotectionMechanism of actionmedicinemedicine.symptomMode of actionReactive Oxygen SpeciesOxidative stressIntracellularCells CulturedCell biochemistry and function
researchProduct

Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression.

2013

This review for the first time summarizes the data obtained in the neuropharmacological studies of mildronate, a drug previously known as a cardioprotective agent. In different animal models of neurotoxicity and neurodegenerative diseases, we demonstrated its neuroprotecting activity. By the use of immunohistochemical methods and Western blot analysis, as well as some selected behavioral tests, the new mechanisms of mildronate have been demonstrated: a regulatory effect on mitochondrial processes and on the expression of nerve cell proteins, which are involved in cell survival, functioning, and inflammation processes. Particular attention is paid to the capability of mildronate to stimulate…

Neurotoxicity SyndromeNerve Tissue ProteinsMitochondrionNeuroprotectionMiceAdjuvants ImmunologicNeuritismedicineAnimalsHumansLearningNeuroinflammationNeuronsbusiness.industryNeurogenesisNeurodegenerationNeurotoxicityParkinson DiseaseGeneral Medicinemedicine.diseaseMitochondriaNerve RegenerationRatsDisease Models AnimalNeuroprotective AgentsSynaptic plasticityNeurotoxicity SyndromesbusinessNeuroscienceMethylhydrazinesMedicina (Kaunas, Lithuania)
researchProduct

Characterization of the transporterB0AT3 (Slc6a17) in the rodent central nervous system.

2013

Abstract Background The vesicular B0AT3 transporter (SLC6A17), one of the members of the SLC6 family, is a transporter for neutral amino acids and is exclusively expressed in brain. Here we provide a comprehensive expression profile of B0AT3 in mouse brain using in situ hybridization and immunohistochemistry. Results We confirmed previous expression data from rat brain and used a novel custom made antibody to obtain detailed co-labelling with several cell type specific markers. B0AT3 was highly expressed in both inhibitory and excitatory neurons. The B0AT3 expression was highly overlapping with those of vesicular glutamate transporter 2 (VGLUT2) and vesicular glutamate transporter 1 (VGLUT1…

Central Nervous SystemMaleSerotonin reuptake inhibitorVesicular glutamate transporter 1Central nervous systemVesicular Transport ProteinsNerve Tissue ProteinsIn situ hybridizationPharmacology and ToxicologyPharmacologyBiologyPlasma Membrane Neurotransmitter Transport ProteinsRats Sprague-DawleyCellular and Molecular NeuroscienceGlutamatergicMiceDopaminePregnancyMonoaminergicmedicineAnimalsRats WistarCells CulturedNeuronsGeneral NeuroscienceNeurosciencesTransporterFarmakologi och toxikologiEmbryo MammalianAntidepressive AgentsRatsMice Inbred C57BLProtein Transportmedicine.anatomical_structureGene Expression Regulationbiology.proteinFemaleFood DeprivationNeurovetenskapermedicine.drugResearch ArticleBMC neuroscience
researchProduct

Mitochondria as the target for mildronate's protective effects in azidothymidine (AZT)-induced toxicity of isolated rat liver mitochondria

2008

Previously mildronate, an aza-butyrobetaine derivative, was shown to be a cytoprotective drug, through its mechanism of action of inhibition of carnitine palmitoyltransferase-1, thus protecting mitochondria from long-chain fatty acid accumulation and subsequent damage. Recently in an azidothymidine (AZT)-induced cardiotoxicity model in vivo (in mice), we have found mildronate's ability of protecting heart tissue from nuclear factor kappaB abnormal expression. Preliminary data also demonstrate cerebro- and hepatoprotecting properties of mildronate in AZT-toxicity models. We suggest that mildronate may target its action predominantly to mitochondria. The present study in isolated rat liver mi…

MaleMitochondrial DiseasesBioenergeticsAntimetabolitesCell RespirationClinical BiochemistryMitochondria LiverIn Vitro TechniquesMitochondrionPharmacologyBiologymedicine.disease_causeBiochemistryPermeabilityRespiratory electron transport chainDrug Delivery SystemsmedicineAnimalsCarnitineRats WistarCardiotoxicityCell BiologyGeneral MedicineRatsDisease Models AnimalMechanism of actionBiochemistryToxicitymedicine.symptomEnergy MetabolismZidovudineOxidative stressMethylhydrazinesmedicine.drug
researchProduct